Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166396983> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W3166396983 endingPage "1056" @default.
- W3166396983 startingPage "1050" @default.
- W3166396983 abstract "Launched in 2002, originator adalimumab (Humira) is the top revenue‐generating drug in the United States. Between 2016 and 2019, the US Food and Drug Administration approved 5 adalimumab biosimilars, yet none have been marketed owing to patent dispute settlements. We sought to calculate the cost of this delayed entry to Medicare over this period by estimating the difference between reported spending on originator adalimumab and estimated spending on originator and biosimilar adalimumab products assuming timely biosimilar market entry. Estimates of potential biosimilar spending were calculated based on the following evidence‐based projections: (i) market capture of 15% for the first biosimilar and 5.5% for successive biosimilars in their first year on the market, and 5% annually thereafter; (ii) price reductions of 3.5% per year and 2.4% per additional biosimilar entry for originator adalimumab; and (iii) price discounts of 25% at launch, 3.4% per year, and 1.7% per additional biosimilar entry for biosimilar adalimumab. Based on these assumptions, had adalimumab biosimilars launched upon approval, estimated non‐rebate spending on them would have been $18.3 million in 2016, $225.7 million in 2017, $436.2 million in 2018, and $727.7 million in 2019, whereas estimated non‐rebate spending on originator adalimumab would have been $2.33 billion, $2.04 billion, $1.78 billion, and $1.42 billion. Cumulative spending on adalimumab would have thus been $8.98 billion instead of an observed $12.11 billion. Accounting for estimated rebates, total predicted savings would have been $2.19 billion. Reforms for timely biosimilar availability will be critical in ensuring optimal savings for Medicare after biosimilar approval." @default.
- W3166396983 created "2021-06-22" @default.
- W3166396983 creator A5033279765 @default.
- W3166396983 creator A5035621209 @default.
- W3166396983 creator A5044094148 @default.
- W3166396983 creator A5074257304 @default.
- W3166396983 date "2021-07-06" @default.
- W3166396983 modified "2023-10-17" @default.
- W3166396983 title "Cost to Medicare of Delayed Adalimumab Biosimilar Availability" @default.
- W3166396983 cites W2732300460 @default.
- W3166396983 cites W2890601525 @default.
- W3166396983 cites W2899736308 @default.
- W3166396983 cites W2965938015 @default.
- W3166396983 cites W3000403758 @default.
- W3166396983 cites W3003979154 @default.
- W3166396983 cites W3009985280 @default.
- W3166396983 cites W3042601447 @default.
- W3166396983 cites W3123866509 @default.
- W3166396983 cites W3126637270 @default.
- W3166396983 cites W849320553 @default.
- W3166396983 doi "https://doi.org/10.1002/cpt.2322" @default.
- W3166396983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34145566" @default.
- W3166396983 hasPublicationYear "2021" @default.
- W3166396983 type Work @default.
- W3166396983 sameAs 3166396983 @default.
- W3166396983 citedByCount "9" @default.
- W3166396983 countsByYear W31663969832021 @default.
- W3166396983 countsByYear W31663969832022 @default.
- W3166396983 countsByYear W31663969832023 @default.
- W3166396983 crossrefType "journal-article" @default.
- W3166396983 hasAuthorship W3166396983A5033279765 @default.
- W3166396983 hasAuthorship W3166396983A5035621209 @default.
- W3166396983 hasAuthorship W3166396983A5044094148 @default.
- W3166396983 hasAuthorship W3166396983A5074257304 @default.
- W3166396983 hasConcept C10138342 @default.
- W3166396983 hasConcept C126322002 @default.
- W3166396983 hasConcept C144133560 @default.
- W3166396983 hasConcept C16051113 @default.
- W3166396983 hasConcept C162853370 @default.
- W3166396983 hasConcept C195487862 @default.
- W3166396983 hasConcept C2779134260 @default.
- W3166396983 hasConcept C2780132546 @default.
- W3166396983 hasConcept C59491497 @default.
- W3166396983 hasConcept C71924100 @default.
- W3166396983 hasConceptScore W3166396983C10138342 @default.
- W3166396983 hasConceptScore W3166396983C126322002 @default.
- W3166396983 hasConceptScore W3166396983C144133560 @default.
- W3166396983 hasConceptScore W3166396983C16051113 @default.
- W3166396983 hasConceptScore W3166396983C162853370 @default.
- W3166396983 hasConceptScore W3166396983C195487862 @default.
- W3166396983 hasConceptScore W3166396983C2779134260 @default.
- W3166396983 hasConceptScore W3166396983C2780132546 @default.
- W3166396983 hasConceptScore W3166396983C59491497 @default.
- W3166396983 hasConceptScore W3166396983C71924100 @default.
- W3166396983 hasIssue "4" @default.
- W3166396983 hasLocation W31663969831 @default.
- W3166396983 hasLocation W31663969832 @default.
- W3166396983 hasOpenAccess W3166396983 @default.
- W3166396983 hasPrimaryLocation W31663969831 @default.
- W3166396983 hasRelatedWork W2984928409 @default.
- W3166396983 hasRelatedWork W3084337600 @default.
- W3166396983 hasRelatedWork W3203482658 @default.
- W3166396983 hasRelatedWork W4232523074 @default.
- W3166396983 hasRelatedWork W4240513502 @default.
- W3166396983 hasRelatedWork W4283023241 @default.
- W3166396983 hasRelatedWork W4311331579 @default.
- W3166396983 hasRelatedWork W4320002525 @default.
- W3166396983 hasRelatedWork W4366241823 @default.
- W3166396983 hasRelatedWork W4384119742 @default.
- W3166396983 hasVolume "110" @default.
- W3166396983 isParatext "false" @default.
- W3166396983 isRetracted "false" @default.
- W3166396983 magId "3166396983" @default.
- W3166396983 workType "article" @default.